Finance

Lists
Why is NXTCL down 5,62%?
Dive Deeper
NXTCL:STO
NextCell Pharma AB
SEK 0,23
-5,62%
(-0,013) 1D
16 Nov., 17:12:13 GMT+1  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for NXTCL...
Open
SEK 0,26
High
SEK 0,26
Low
SEK 0,22
Mkt. cap
28,63 m
Avg. vol.
1,00 m
Volume
396,66 k
52-wk high
SEK 1,78
52-wk low
SEK 0,20
EPS
-SEK 0,45
Shares outstanding
111,39 m
No. of employees
21
Open
SEK 0,26
High
SEK 0,26
Low
SEK 0,22
Mkt. cap
28,63 m
Avg. vol.
1,00 m
Volume
396,66 k
52-wk high
SEK 1,78
52-wk low
SEK 0,20
EPS
-SEK 0,45
Shares outstanding
111,39 m
No. of employees
21
News stories
From web sources and news partners
Profile
NextCell Pharma AB is a Swedish biopharmaceutical company headquartered in Huddinge, in the Flemingsberg life-science cluster south of Stockholm. The company develops allogeneic mesenchymal stromal cell therapies, with its lead candidate aimed at preserving insulin production in newly diagnosed type 1 diabetes. Alongside its drug development programme, NextCell operates a private umbilical cord stem cell bank and a contract manufacturing and analytical services subsidiary for Advanced Therapy Medicinal Products. NextCell's shares trade on the Nasdaq First North Growth Market in Stockholm under the ticker NXTCL. Wikipedia
About NextCell Pharma AB
CEOMathias Svahn
Employees21
Founded19 Mrt. 2014
Headquarters-
SectorHealth Care
Industry-
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
Mei 2025
Aug. 2025
Mrt. 2026
Jun. 2026
Revenue
2,26 m
1,83 m
2,78 m
3,03 m
Cost of goods sold
2,11 m
1,93 m
1,82 m
1,90 m
Cost of revenue
2,11 m
2,20 m
1,82 m
1,90 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,69 m
13,20 m
10,88 m
12,21 m
Operating expense
10,50 m
9,11 m
11,43 m
12,86 m
Total operating expenses
12,62 m
15,72 m
13,25 m
14,76 m
Operating income
-10,35 m
-13,90 m
-10,46 m
-11,73 m
Other non operating income
-
-1,00
-
-
EBT including unusual items
-10,27 m
-13,79 m
-10,39 m
-11,68 m
EBT excluding unusual items
-10,27 m
-13,79 m
-10,39 m
-11,68 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
201,47 k
-120,48 k
-81,33 k
37,36 k
Net income
-10,27 m
-13,79 m
-10,39 m
-11,68 m
Net profit margin
-454,15%
-342,26%
-373,25%
-384,77%
Earnings per share
-
-
-
-
Interest and investment income
82,25 k
162,24 k
79,47 k
50,96 k
Interest expense
-
-1,59 k
-1,19 k
-188,00
Net interest expenses
82,25 k
109,02 k
78,28 k
50,78 k
Depreciation and amortization charges
615,41 k
638,32 k
625,24 k
616,94 k
EBITDA
-9,74 m
-13,26 m
-9,84 m
-11,11 m
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google-programme